After announcing plans to move to New Jersey in November, multispecialty health care company Allergan Inc. has signed a lease to open a 93,000-square-foot research and development facility in Bridgewater — creating several hundred jobs and injecting about $12 million in private investment into the state’s economy within the next three to five years.
Allergan — which produces pharmaceuticals and biologics, including Botox — will open its facility in Somerset Corporate Center II, a 250,000-square-foot, class A facility owned by SJP Properties that houses the New Jersey branches of Qualcomm Inc., Merrill Lynch & Co. Inc. and Dr. Reddy’s Laboratories Ltd. The property is seeking LEED certification as an environmentally friendly building.
“We are extremely confident that Allergan will strongly benefit from this property’s strategic location within the heart of New Jersey’s pharma and tech corridor, offering unparalleled access to a highly skilled labor pool,” said Steven J. Pozycki, CEO of SJP Properties, in a statement.
In September, Gov. Chris Christie met with Allergan officials to discuss the company’s expansion plans and showcase New Jersey as a cornerstone for health care and life sciences. When Allergan agreed to open an R&D center in November, Christie said it was “the latest indication that the ‘Jersey Comeback’ has begun.”
“Allergan’s decision to expand its operations in New Jersey … is proof that the pro-business policies of this administration are helping to attract and retain both large and small businesses here in the state,” Christie said at last year’s announcement.
In November, Allergan was approved for a Business Employment Incentive Program grant from the Economic Development Authority, worth $14.9 million over 10 years, as an incentive to open a facility in the state and create 387 new jobs, according to an EDA spokeswoman.